{"entity":{"type":"insider","cik":"0001873905","url":"/insider/0001873905","json_url":"/insider/0001873905.json","name":"Tak Paul Peter","name_source":"as-filed","also_issuer":false,"cross_url":null},"coverage_statement":{"n_transactions":10,"n_filings":8,"first":"2021-08-02","last":"2025-03-20","span_basis":"filed_date"},"name_variants":[{"name":"Tak Paul Peter","source":"filing","n_filings":8,"first_seen":"2021-08-02","last_seen":"2025-03-20"}],"transactions":[{"id":4981621,"accession":"0000950170-25-042725","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0000950170-25-042725","line_url":"/filing/0000950170-25-042725#line-2","is_derivative":false,"issuer_cik":"0001841387","issuer_name":"Candel Therapeutics, Inc.","issuer_ticker":"CADL","issuer_name_source":null,"issuer_url":"/issuer/0001841387","owner_cik":"0001873905","owner_name":"Tak Paul Peter","owner_display_name":"Tak Paul Peter","owner_url":"/insider/0001873905","role":"Director, Officer (Chief Executive Officer)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Executive Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":400.0,"shares_display":"400","price_per_share":9.0025,"price_display":"9.00","price_state":"stated","total_value":3601.0,"total_display":"3,601.00","total_whole":"3,601","shares_owned_after":225740.0,"shares_owned_after_display":"225,740","ownership_form":"D","is_10b5_1":null,"transaction_date":"2025-03-19","filed_date":"2025-03-20","scope":"insider"},{"id":4981614,"accession":"0000950170-25-042725","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0000950170-25-042725","line_url":"/filing/0000950170-25-042725#line-1","is_derivative":false,"issuer_cik":"0001841387","issuer_name":"Candel Therapeutics, Inc.","issuer_ticker":"CADL","issuer_name_source":null,"issuer_url":"/issuer/0001841387","owner_cik":"0001873905","owner_name":"Tak Paul Peter","owner_display_name":"Tak Paul Peter","owner_url":"/insider/0001873905","role":"Director, Officer (Chief Executive Officer)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Executive Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":25772.0,"shares_display":"25,772","price_per_share":8.7701,"price_display":"8.77","price_state":"stated","total_value":226023.0172,"total_display":"226,023.02","total_whole":"226,023","shares_owned_after":226140.0,"shares_owned_after_display":"226,140","ownership_form":"D","is_10b5_1":null,"transaction_date":"2025-03-18","filed_date":"2025-03-20","scope":"insider"},{"id":4415336,"accession":"0000950170-25-006724","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0000950170-25-006724","line_url":"/filing/0000950170-25-006724#line-1","is_derivative":false,"issuer_cik":"0001841387","issuer_name":"Candel Therapeutics, Inc.","issuer_ticker":"CADL","issuer_name_source":null,"issuer_url":"/issuer/0001841387","owner_cik":"0001873905","owner_name":"Tak Paul Peter","owner_display_name":"Tak Paul Peter","owner_url":"/insider/0001873905","role":"Director, Officer (Chief Executive Officer)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Executive Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":21704.0,"shares_display":"21,704","price_per_share":7.225,"price_display":"7.22","price_state":"stated","total_value":156811.4,"total_display":"156,811.40","total_whole":"156,811","shares_owned_after":251912.0,"shares_owned_after_display":"251,912","ownership_form":"D","is_10b5_1":null,"transaction_date":"2025-01-15","filed_date":"2025-01-17","scope":"insider"},{"id":4871975,"accession":"0000950170-25-004198","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0000950170-25-004198","line_url":"/filing/0000950170-25-004198#line-1","is_derivative":false,"issuer_cik":"0001841387","issuer_name":"Candel Therapeutics, Inc.","issuer_ticker":"CADL","issuer_name_source":null,"issuer_url":"/issuer/0001841387","owner_cik":"0001873905","owner_name":"Tak Paul Peter","owner_display_name":"Tak Paul Peter","owner_url":"/insider/0001873905","role":"Director, Officer (Chief Executive Officer)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Executive Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":21172.0,"shares_display":"21,172","price_per_share":8.2182,"price_display":"8.22","price_state":"stated","total_value":173995.7304,"total_display":"173,995.73","total_whole":"173,996","shares_owned_after":273616.0,"shares_owned_after_display":"273,616","ownership_form":"D","is_10b5_1":null,"transaction_date":"2025-01-08","filed_date":"2025-01-10","scope":"insider"},{"id":2833923,"accession":"0000950170-24-132930","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0000950170-24-132930","line_url":"/filing/0000950170-24-132930#line-1","is_derivative":false,"issuer_cik":"0001841387","issuer_name":"Candel Therapeutics, Inc.","issuer_ticker":"CADL","issuer_name_source":null,"issuer_url":"/issuer/0001841387","owner_cik":"0001873905","owner_name":"Tak Paul Peter","owner_display_name":"Tak Paul Peter","owner_url":"/insider/0001873905","role":"Director, Officer (Chief Executive Officer)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Executive Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":48847.0,"shares_display":"48,847","price_per_share":4.5556,"price_display":"4.56","price_state":"stated","total_value":222527.3932,"total_display":"222,527.39","total_whole":"222,527","shares_owned_after":294788.0,"shares_owned_after_display":"294,788","ownership_form":"D","is_10b5_1":null,"transaction_date":"2024-11-29","filed_date":"2024-12-03","scope":"insider"},{"id":2082468,"accession":"0000950170-24-084761","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0000950170-24-084761","line_url":"/filing/0000950170-24-084761#line-1","is_derivative":false,"issuer_cik":"0001841387","issuer_name":"Candel Therapeutics, Inc.","issuer_ticker":"CADL","issuer_name_source":null,"issuer_url":"/issuer/0001841387","owner_cik":"0001873905","owner_name":"Tak Paul Peter","owner_display_name":"Tak Paul Peter","owner_url":"/insider/0001873905","role":"Director, Officer (Chief Executive Officer)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Executive Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":22528.0,"shares_display":"22,528","price_per_share":6.4726,"price_display":"6.47","price_state":"stated","total_value":145814.7328,"total_display":"145,814.73","total_whole":"145,815","shares_owned_after":330735.0,"shares_owned_after_display":"330,735","ownership_form":"D","is_10b5_1":null,"transaction_date":"2024-07-17","filed_date":"2024-07-19","scope":"insider"},{"id":2950599,"accession":"0000950170-24-083401","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0000950170-24-083401","line_url":"/filing/0000950170-24-083401#line-1","is_derivative":false,"issuer_cik":"0001841387","issuer_name":"Candel Therapeutics, Inc.","issuer_ticker":"CADL","issuer_name_source":null,"issuer_url":"/issuer/0001841387","owner_cik":"0001873905","owner_name":"Tak Paul Peter","owner_display_name":"Tak Paul Peter","owner_url":"/insider/0001873905","role":"Director, Officer (Chief Executive Officer)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Executive Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":20293.0,"shares_display":"20,293","price_per_share":5.9734,"price_display":"5.97","price_state":"stated","total_value":121218.2062,"total_display":"121,218.21","total_whole":"121,218","shares_owned_after":353263.0,"shares_owned_after_display":"353,263","ownership_form":"D","is_10b5_1":null,"transaction_date":"2024-07-11","filed_date":"2024-07-15","scope":"insider"},{"id":6279163,"accession":"0001209191-22-060689","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001209191-22-060689","line_url":"/filing/0001209191-22-060689#line-2","is_derivative":false,"issuer_cik":"0001841387","issuer_name":"Candel Therapeutics, Inc.","issuer_ticker":"CADL","issuer_name_source":null,"issuer_url":"/issuer/0001841387","owner_cik":"0001873905","owner_name":"Tak Paul Peter","owner_display_name":"Tak Paul Peter","owner_url":"/insider/0001873905","role":"Director, Officer (Chief Executive Officer)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Executive Officer","security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":12935.0,"shares_display":"12,935","price_per_share":1.92,"price_display":"1.92","price_state":"stated","total_value":24835.2,"total_display":"24,835.20","total_whole":"24,835","shares_owned_after":40985.0,"shares_owned_after_display":"40,985","ownership_form":"D","is_10b5_1":null,"transaction_date":"2022-12-09","filed_date":"2022-12-12","scope":"insider"},{"id":6279158,"accession":"0001209191-22-060689","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001209191-22-060689","line_url":"/filing/0001209191-22-060689#line-1","is_derivative":false,"issuer_cik":"0001841387","issuer_name":"Candel Therapeutics, Inc.","issuer_ticker":"CADL","issuer_name_source":null,"issuer_url":"/issuer/0001841387","owner_cik":"0001873905","owner_name":"Tak Paul Peter","owner_display_name":"Tak Paul Peter","owner_url":"/insider/0001873905","role":"Director, Officer (Chief Executive Officer)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Executive Officer","security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":3050.0,"shares_display":"3,050","price_per_share":1.7,"price_display":"1.70","price_state":"stated","total_value":5185.0,"total_display":"5,185.00","total_whole":"5,185","shares_owned_after":28050.0,"shares_owned_after_display":"28,050","ownership_form":"D","is_10b5_1":null,"transaction_date":"2022-12-08","filed_date":"2022-12-12","scope":"insider"},{"id":4087850,"accession":"0000899243-21-031097","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0000899243-21-031097","line_url":"/filing/0000899243-21-031097#line-1","is_derivative":false,"issuer_cik":"0001841387","issuer_name":"Candel Therapeutics, Inc.","issuer_ticker":"CADL","issuer_name_source":null,"issuer_url":"/issuer/0001841387","owner_cik":"0001873905","owner_name":"Tak Paul Peter","owner_display_name":"Tak Paul Peter","owner_url":"/insider/0001873905","role":"Director, Officer (Chief Executive Officer)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Executive Officer","security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":25000.0,"shares_display":"25,000","price_per_share":8.0,"price_display":"8.00","price_state":"stated","total_value":200000.0,"total_display":"200,000.00","total_whole":"200,000","shares_owned_after":25000.0,"shares_owned_after_display":"25,000","ownership_form":"D","is_10b5_1":null,"transaction_date":"2021-07-29","filed_date":"2021-08-02","scope":"insider"}],"collapsed":true,"next_cursor":null,"ledger_fault":false,"count":{"value":10,"kind":"exact"},"open_market_only":false,"composition":{"kind":"exact","rows":[{"code":"P","label":"Open-market purchase","n":3,"open_market":true},{"code":"S","label":"Open-market sale","n":7,"open_market":true},{"code":"M","label":"Option exercise","n":0,"open_market":false},{"code":"A","label":"Grant or award","n":0,"open_market":false},{"code":"F","label":"Tax withholding","n":0,"open_market":false},{"code":"D","label":"Disposition to the issuer","n":0,"open_market":false},{"code":"X","label":"In-the-money option exercise","n":0,"open_market":false}],"total":10},"affiliations":[{"type":"issuer","type_label":"ISSUER","cik":"0001841387","name":"Candel Therapeutics, Inc.","url":"/issuer/0001841387","role":"Director, Officer (Chief Executive Officer)","n_filings":8,"first_seen":"2021-08-02","last_seen":"2025-03-20"}],"order_statement":"Newest transaction date first, id breaking the tie.","canonical_url":"https://ebomi.com/insider/0001873905","retrieved_at":"2026-08-26T15:35:25+00:00","coverage":{"filings":1506293,"transactions":4290787,"issuers":28597,"insiders":152303,"first_filed_date":"2003-06-30","last_filed_date":"2026-08-25","last_ingest":"2026-08-26T05:24:25.741053+00:00","counts_are":{"filings":"estimate","transactions":"estimate","issuers":"estimate","insiders":"estimate"},"source":"SEC EDGAR Form 4 filings, parsed by ebomi","fault":false},"license":{"underlying_records":"US SEC filings are public records of the United States government and are not subject to copyright. The transactional facts in them are not ours to license.","this_presentation":"The parsing, normalisation, curation, and presentation are ebomi's own work.","grant":"undecided","grant_note":"The open licence for ebomi's own layer is an open owner decision (SPEC-20260731T1159Z open question 3: CC BY 4.0 or CC0 with a citation request). Until it is taken, no grant is asserted here.","citation_request":"Balogh, A. Insider trading. Scientific Data 10, 237 (2023)","url":"https://ebomi.com/license"},"fair_use":{"policy":"These JSON endpoints are open and unauthenticated. Please read them at a human pace, identify your client in the User-Agent header, and use the published dataset for bulk work rather than crawling page by page.","bulk_alternative":"doi:10.1038/s41597-023-02147-6"}}